Scopolamine is a well known muscarinic cholinergic competitive antagonist involved in human and animal memory processes, particularly in the processes of learning acquisition and short-term memory. As deficiencies of brain acetylcholine and decreasing in the neurotransmitter synthesis have been accounted as common features in Alzheimer’s disease (AD), scopolamine has been one of the most used drugs to induce animal models of AD. Also, there is an increased awareness regarding the relevance of the oxidative stress in the progression of AD. In this context, we were interested in studying the effects that scopolamine induction of a rat model of Alzheimer disease has on oxidative stress, expressed by the Total Antioxidant Status. Our experimental data indicates that the blockade of the muscarinic receptors by the administration of scopolamine has a significant prooxidant effect for this compound, which is manifested by a decrease in the TAS of the temporal lobe compared to the control group of rats.